SYRE vs HALO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SYRE · Spyre Therapeutics$93.47 ▼ 4.26%
HALO · Halozyme Therapeutics$91.35 ▼ 1.82%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SYRE +246.6%
- HALO +23.4%
Head to head
| Metric | SYRE | HALO |
|---|---|---|
| Price | $93.47 | $91.35 |
| Change today | ▼ 4.26% | ▼ 1.82% |
| Market cap | $8.88B | $10.41B |
| Return, 3 months | -12.4% | -15.9% |
| Return, year to date | +185.3% | +35.7% |
| Return, 1 year | +285.3% | +29.9% |
| P/E (TTM) | – | 22.8 |
| P/B | 9.8 | -188.4 |
| P/E percentile vs own 5y | 8th | 65th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +39.2% |
| Net profit growth (YoY) | -759.5% | +41.0% |
| Gross margin | – | 82.3% |
| Operating margin | – | 55.9% |
| Net margin | – | 26.9% |
| Return on equity | -42.0% | 216.4% |
| Analyst target vs. price | +32.0% | +37.5% |
| Analyst buy share | 100% | 80% |
| RSI (14) | 46 | 20 |
| 30-day volatility | 65.3% | 60.1% |
| Max drawdown, 1 year | -27.8% | -30.4% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HALO is the largest of the group by market value.
- SYRE has returned the most over the past year.
- HALO has been the calmest stock over the last 30 days.